Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry.
Phase of Trial: Phase I
Latest Information Update: 11 Aug 2016
At a glance
- Drugs Triciribine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 30 Jun 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 30 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.